An investigation on behalf of investors of Mylan N.V. (NASDAQ: MYL) shares over potential securities laws violations by Mylan N.V. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Mylan N.V. (NASDAQ: MYL) concerning whether a series of statements by Mylan N.V. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

United Kingdom based Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. Mylan N.V. reported that its annual Total Revenue declined from over $11.9 billion in 2017 to over $11.43 billion in 2018 and that its Net Income declined from $696 Million in 2017 to $352.5 million in 2018.